These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 20953137

  • 1. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
    Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F.
    Cancer Biol Ther; 2010 Dec 01; 10(11):1201-14. PubMed ID: 20953137
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
    Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A.
    Blood; 2008 Sep 15; 112(6):2450-62. PubMed ID: 18583568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.
    Szegezdi E, Cahill S, Meyer M, O'Dwyer M, Samali A.
    Br J Cancer; 2006 Feb 13; 94(3):398-406. PubMed ID: 16434995
    [Abstract] [Full Text] [Related]

  • 8. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
    Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J.
    Br J Haematol; 2017 Dec 13; 179(5):756-771. PubMed ID: 29048129
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
    Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH.
    J Biol Chem; 2009 May 08; 284(19):12886-95. PubMed ID: 19279006
    [Abstract] [Full Text] [Related]

  • 14. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
    Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T.
    Cancer Sci; 2006 Jun 08; 97(6):540-5. PubMed ID: 16734734
    [Abstract] [Full Text] [Related]

  • 15. Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms.
    Akay C, Thomas C, Gazitt Y.
    Cell Cycle; 2004 Mar 08; 3(3):324-34. PubMed ID: 14726646
    [Abstract] [Full Text] [Related]

  • 16. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS.
    Cancer Res; 2008 Jan 01; 68(1):266-75. PubMed ID: 18172319
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
    Boyko-Fabian M, Niehr F, Distel L, Budach V, Tinhofer I.
    PLoS One; 2014 Jan 01; 9(6):e98867. PubMed ID: 24927258
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.